sulfinpyrazone has been researched along with Diabetic Nephropathies in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pannebakker, MA | 1 |
| den Ottolander, GJ | 1 |
| ten Pas, JG | 1 |
1 trial available for sulfinpyrazone and Diabetic Nephropathies
| Article | Year |
|---|---|
Insulin requirements in diabetic patients treated with sulphinpyrazone.
Topics: Adult; Aged; Body Weight; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drug Inter | 1979 |